PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: An analysis of 10 clinical trials and the LDL receptor's role

Journal of Lipid Research

Volumn 57, Issue 6, 2016, Pages 1086-1096

  Raal, Frederick J ^a   Giugliano, Robert P ^b   Sabatine, Marc S ^b   Koren, Michael J ^c   Blom, Dirk ^d   Seidah, Nabil G ^e   Honarpour, Narimon ^f   Lira, Armando ^f   Xue, Allen ^f   Chiruvolu, Padmaja ^f   Jackson, Simon ^f   Di, Mei ^f   Peach, Matthew ^f   Somaratne, Ransi ^f   Wasserman, Scott M ^f   Scott, Rob ^f   Stein, Evan A ^g  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jacksonville Center for Clinical Research   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^f AMGEN INC   (United States)

^g Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

Lipoprotein (a); Low density lipoprotein cholesterol; Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

EVOLOCUMAB; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; LDLR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLUORESCENCE ANALYSIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); HEP-G2 CELL LINE; IMMUNOLOGY; META ANALYSIS; METABOLISM;

ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HEP G2 CELLS; HUMANS; LIPOPROTEIN(A); MALE; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL;

EID: 84971539123     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P065334     Document Type: Article

References (44)

1. Utermann, G. 1989. The mysteries of lipoprotein(a). Science. 246: 904-910.
2. Erqou, S., S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh; Emerging Risk Factors Collaboration. 2009. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 302: 412-423.
3. Nordestgaard, B. G., M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, et al; European Atherosclerosis Society Consensus Panel. 2010. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31: 2844-2853.
4. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al; PROCARDIS Consortium. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
5. Hernández, C., G. Francisco, A. Ciudin, P. Chacón, B. Montoro, G. Llaverias, F. Blanco-Vaca, and R. Simó. 2011. Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial. Diabetes Metab. 37: 124-130.
6. Gonbert, S., S. Malinsky, A. C. Sposito, H. Laouenan, C. Doucet, M. J. Chapman, and J. Thillet. 2002. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis. 164: 305-311.
7. Crouse 3rd, J. R., J. Frohlich, L. Ose, M. Mercuri, and J. A. Tobert. 1999. Effects of high doses of simvastatin and atorvastatin on highdensity lipoprotein cholesterol and apolipoprotein A-I. Am. J. Cardiol. 83: 1476-1477, A7.
8. Hunninghake, D. B., E. A. Stein, and M. J. Mellies. 1993. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J. Clin. Pharmacol. 33: 574-580.
9. Fieseler, H. G., V. W. Armstrong, E. Wieland, J. Thiery, E. Schütz, A. K. Walli, and D. Seidel. 1991. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. Clin. Chim. Acta. 204: 291-300.
10. Irudayam, J. B., R. Sivaraj, and P. Nirmala. 2014. Effect of statins on lipoprotein (a) in dyslipidemic patients. Int. J. Basic Clin. Pharmacol. 3: 1024-1029.
11. Romagnuolo, R., C. A. Scipione, M. B. Boffa, S. M. Marcovina, N. G. Seidah, and M. L. Koschinsky. 2015. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J. Biol. Chem. 290: 11649-11662.
12. Kostner, G. M., D. Gavish, B. Leopold, K. Bolzano, M. S. Weintraub, and J. L. Breslow. 1989. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 80: 1313-1319.
13. Yeang, C., M-Y. Hung, Y-S. Byun, P. Clopton, X. Yang, J. L. Witztum, and S. Tsimikas. 2016. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J. Clin. Lipidol. In press.
14. Berg, K., G. Dahlén, B. Christophersen, T. Cook, J. Kjekshus, and T. Pedersen. 1997. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52: 254-261.
15. Raal, F. J., R. P. Giugliano, M. S. Sabatine, M. J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. M. Wasserman, et al. 2014. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63: 1278-1288.
16. Gaudet, D., D. J. Kereiakes, J. M. McKenney, E. M. Roth, C. Hanotin, D. Gipe, Y. Du, A. C. Ferrand, H. N. Ginsberg, and E. A. Stein. 2014. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am. J. Cardiol. 114: 711-715.
17. Dias, C. S., A. J. Shaywitz, S. M. Wasserman, B. P. Smith, B. Gao, D. S. Stolman, C. P. Crispino, K. V. Smirnakis, M. G. Emery, A. Colbert, et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60: 1888-1898.
18. Sullivan, D., A. G. Olsson, R. Scott, J. B. Kim, A. Xue, V. Gebski, S. M. Wasserman, and E. A. Stein. 2012. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 308: 2497-2506.
19. Koren, M. J., R. Scott, J. B. Kim, B. Knusel, T. Liu, L. Lei, M. Bolognese, and S. M. Wasserman. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 380: 1995-2006.
20. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
21. Giugliano, R. P., N. R. Desai, P. Kohli, W. J. Rogers, R. Somaratne, F. Huang, T. Liu, S. Mohanavelu, E. B. Hoffman, S. T. McDonald, et al; LAPLACE-TIMI 57 Investigators. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 380: 2007-2017.
22. Sun, H., A. Samarghandi, N. Zhang, Z. Yao, M. Xiong, and B. B. Teng. 2012. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32: 1585-1595.
23. Koren, M. J., P. Lundqvist, M. Bolognese, J. M. Neutel, M. L. Monsalvo, J. Yang, J. B. Kim, R. Scott, S. M. Wasserman, and H. Bays; MENDEL-2 Investigators. 2014. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Coll. Cardiol. 63: 2531-2540.
24. Robinson, J. G., B. S. Nedergaard, W. J. Rogers, J. Fialkow, J. M. Neutel, D. Ramstad, R. Somaratne, J. C. Legg, P. Nelson, R. Scott, et al; LAPLACE-2 Investigators. 2014. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 311: 1870-1882.
25. Raal, F., R. Scott, R. Somaratne, I. Bridges, G. Li, S. M. Wasserman, and E. A. Stein. 2012. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 126: 2408-2417.
26. Raal, F. J., E. A. Stein, R. Dufour, T. Turner, F. Civeira, L. Burgess, G. Langslet, R. Scott, A. G. Olsson, D. Sullivan, et al; RUTHERFORD-2 Investigators. 2015. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebocontrolled trial. Lancet. 385: 331-340.
27. Stroes, E., D. Colquhoun, D. Sullivan, F. Civeira, R. S. Rosenson, G. F. Watts, E. Bruckert, L. Cho, R. Dent, B. Knusel, et al; GAUSS-2 Investigators. 2014. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63: 2541-2548.
28. Koren, M. J., R. P. Giugliano, F. J. Raal, D. Sullivan, M. Bolognese, G. Langslet, F. Civeira, R. Somaratne, P. Nelson, T. Liu, et al; OSLER Investigators. 2014. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 129: 234-243.
29. Seman, L. J., and W. C. Breckenridge. 1986. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem. Cell Biol. 64: 999-1009.
30. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
31. Henne, K. R., B. Ason, M. Howard, W. Wang, J. Sun, J. Higbee, J. Tang, K. C. Matsuda, R. Xu, L. Zhou, et al. 2015. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinitydependent and exhibit limited sensitivity to neonatal Fc receptorbinding enhancement. J. Pharmacol. Exp. Ther. 353: 119-131.
32. Dietschy, J. M., and S. D. Turley. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12: 105-112.
33. Armstrong, V. W., B. Harrach, H. Robenek, M. Helmhold, A. K. Walli, and D. Seidel. 1990. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J. Lipid Res. 31: 429-441.
34. Armstrong, V. W., A. K. Walli, and D. Seidel. 1985. Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J. Lipid Res. 26: 1314-1323.
35. Canuel, M., X. Sun, M. C. Asselin, E. Paramithiotis, A. Prat, and N. G. Seidah. 2013. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 8: e64145.
36. Gustafsen, C., M. Kjolby, M. Nyegaard, M. Mattheisen, J. Lundhede, H. Buttenschøn, O. Mors, J. F. Bentzon, P. Madsen, A. Nykjaer, et al. 2014. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 19: 310-318.
37. Liu, M., G. Wu, J. Baysarowich, M. Kavana, G. H. Addona, K. K. Bierilo, J. S. Mudgett, G. Pavlovic, A. Sitlani, J. J. Renger, et al. 2010. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J. Lipid Res. 51: 2611-2618.
38. Poirier, S., G. Mayer, S. Benjannet, E. Bergeron, J. Marcinkiewicz, N. Nassoury, H. Mayer, J. Nimpf, A. Prat, and N. G. Seidah. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283: 2363-2372.
39. Shan, L., L. Pang, R. Zhang, N. J. Murgolo, H. Lan, and J. A. Hedrick. 2008. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375: 69-73.
40. Argraves, K. M., K. F. Kozarsky, J. T. Fallon, P. C. Harpel, and D. K. Strickland. 1997. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J. Clin. Invest. 100: 2170-2181.
41. Yang, X. P., M. J. Amar, B. Vaisman, A. V. Bocharov, T. G. Vishnyakova, L. A. Freeman, R. J. Kurlander, A. P. Patterson, L. C. Becker, and A. T. Remaley. 2013. Scavenger receptor-BI is a receptor for lipoprotein(a). J. Lipid Res. 54: 2450-2457.
42. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. J. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Geary, et al. 2015. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386: 1472-1483.
43. Sabatine, M. S., R. P. Giugliano, A. Keech, N. Honarpour, H. Wang, T. Liu, S. M. Wasserman, R. Scott, P. S. Sever, and T. R. Pedersen. 2016. Rationale and design of the further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk trial. Am. Heart J. 173: 94-101.
44. Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.